
    
      This is a 6-month multi-center, open-label, long-term safety extension study in subjects who
      have completed Study 060-633 (NCT00953147). This study is designed to evaluate the long-term
      safety of ciclesonide HFA nasal aerosol 160 Î¼g administered once-daily to male and female
      subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR). This study was
      previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon
      Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    
  